(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2021 (10.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/176434 A1

(51) International Patent Classification:
A61K 39/12 (2006.01) *A61K 39/00* (2006.01)
A61P 31/14 (2006.01)

(21) International Application Number:
PCT/IB2021/052858

(22) International Filing Date:
06 April 2021 (06.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/983,737	01 March 2020 (01.03.2020)	US
20168324.0	06 April 2020 (06.04.2020)	EP
20202124.2	15 October 2020 (15.10.2020)	EP
20211936.8	04 December 2020 (04.12.2020)	EP
21154645.2	01 February 2021 (01.02.2021)	EP
PCT/US2021/020313	01 March 2021 (01.03.2021)	US
21160933.4	05 March 2021 (05.03.2021)	EP

(71) Applicants: **VALNEVA AUSTRIA GMBH** [AT/AT]; Campus Vienna Biocenter 3, 1030 Vienna (AT). **DYNAVAX TECHNOLOGIES CORPORATION** [US/US]; 2100 Powell Street, Suite 900, Emeryville, California, 94608 (US).

(72) Inventors: **MEINKE, Andreas**; Lastbergstrasse 84, 3031 Pressbaum (AT). **MÖHLEN, Michael**; Margaretenplatz 7/12, 1050 Vienna (AT). **REINISCH, Christoph**; Hochweg 25, 2500 Siegenfeld (AT). **SCHLEGL, Robert**; Rosental 63, 2500 Siegenfeld (AT). **TAUCHER, Christian**; Georgistrasse 131, 1210 Vienna (AT). **CAMPBELL, John D.**; c/o Dynavax Technologies Corporation, 2100 Powell Street, Suite 900, Emeryville, California, 94608 (US). **NOVACK, David**; c/o Dynavax Technologies Corporation, 2100 Powell Street, Suite 900, Emeryville, California, 94608 (US). **JANSSEN, Robert S.**; c/o Dynavax Technologies Corporation, 2100 Powell Street, Suite 900, Emeryville, California, 94608 (US).

(74) Agent: **LEPPARD, Andrew** et al.; Script IP Limited, Turnpike House, 18 Bridge Street, Frome Somerset BA11 1BB (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with information concerning request for restoration of the right of priority in respect of one or more priority claims (Rules 26bis.3 and 48.2(b)(vii))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: CPG-ADJUVANTED SARS-COV-2 VIRUS VACCINE

(57) Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

WO 2021/176434 A1